Elimination of viral hepatitis: Global perspective- Zhongdan Chen, PhD

Asian Conference on Hepatitis and AIDS (ACHA) 2018

Treatment of CHB in China: Experience and evidence from real-world studies- Jidong Jia, MD, PhD

Asian Conference on Hepatitis and AIDS (ACHA) 2018

Non-viral liver diseases in China- Zhongping Duan, MD, PhD

Asian Conference on Hepatitis and AIDS (ACHA) 2018

CHB treatment with Chinese medicine and NAs- Yongping Yang, MD

Asian Conference on Hepatitis and AIDS (ACHA) 2018

CHB treatment with Chinese medicine and NAs- Yongping Yang, MD

Asian Conference on Hepatitis and AIDS (ACHA) 2018

Efficacy and tolerability of grazoprevir and elbasvir in peginterferon alfa plus ribavirin experienced patients with chronic genotype 1 HCV and HIV co-infection: A nonrandomised, open-label clinical trial- Chien-Yu Cheng

Asian Conference on Hepatitis and AIDS (ACHA) 2018

HIV-1/HCV co-infection treatment with single-tablet antiviral regimens (CoSTARs): 12 Weeks of Ledipasvir/ Sofosbuvir (LDV/SOF) after randomized switch to Elvitegravir/Cobicistat/ Emtricitabine/Tenofovir alafenamide (E/C/F/TAF) or rilpivirin- Damian Mccoll

Asian Conference on Hepatitis and AIDS (ACHA) 2018

New indicators for the evaluation of hepatitis B therapy- Xinxin Zhang, MD, PhD

Asian Conference on Hepatitis and AIDS (ACHA) 2018

Sequential cross-section study on hepatitis viruses infection in Chinese AIDS patients- Lin Liu, MD

Asian Conference on Hepatitis and AIDS (ACHA) 2018

Non-alcoholic fatty liver disease in China- Jiangao Fan, MD, PhD

Asian Conference on Hepatitis and AIDS (ACHA) 2018

Specific Complex Interactions (mechanic presentation) | David Burger, PharmD, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Backing up clinical data with modelling | Marco Siccardi, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Back-terial co-infections | Mohammed Lamorde, FRCP, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

The ‘Back Side’ of Compartments | Saye Khoo, MD, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Will we see the Back of DDIs? | Catia Marzolini, PharmD, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Pharmacogenetics - Back to reality | Andrew Owen, BSS, MSC, PhD, FSB

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Looking Backwards: Hormonal Contraception and ART | Kimberly Scarsi, PharmD, MS, FCCP

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Janssen - Rilpivirine | Herta Crauwels, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Target Concentrations | Angela Kashuba, PharmD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

The FDA Perspective on Hepatitis C Drug Resistance | Patrick Harrington, PHD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Other Viruses: using Wolbachia to interrupt transmission of viral infections such as Dengue, Chikungunya and Zika | Steven Kern, PhD

International Workshop on Clinical Pharmacology of Tuberculosis Drugs 2016

Acute Hepatitis C Infection | Christoph Boesecke, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV 2015

State of the Art Treatment of Hepatitis B | Maria Buti, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV 2015

Epidemiology of Hepatitis B in Central and Eastern Europe | Adrian Streinu Cercel, MD, PhD

Central and Eastern European Meeting on Viral Hepatitis and Co-infection with HIV 2015